Roche said its $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results